The beneficial effect of oestrogen on blood vessels may include modulation of vascular response to injury. In this experiment we set out to develop an in-vitro model, using all human materials, for the study of vascular changes in culture, and their response to oestrogen treatment. Human ovarian vein segments were obtained from 15 hysterectomy specimens, and cultured with and without the addition of 17β-oestradiol. Paired control veins were cultured with the inert 17α-oestradiol. The veins were stained with anti-α-smooth muscle actin and Miller's elastin, and intimal thickness measured. Cultured veins developed a significant degree of intimal thickening [15.7 versus 8.25 µm in fresh veins, 95% confidence intervals (CI) 13.6, 17.8 and 6.3, 10.2 respectively; P ϭ 0.0001]. The addition of 17β-oestradiol, but not 17α-oestradiol, led to a significant reduction in intimal hyperplasia (intimal thickness 8.85 µm; 95% CI 6.9, 10.8; P ϭ 0.008). The mean number of nuclei per highpower field was also significantly lower in the intima of oestrogen-treated compared to untreated veins (11.6; 95% CI 9.9, 13.26 versus 14.05; 95% CI 12.5, 15.6; P ϭ 0.001). Our data suggest that intimal hyperplasia in cultured ovarian veins is effectively reduced by oestrogen. Key words: cultured human ovarian veins/intimal hyperplasia/ oestrogen/postmenopausal Introduction As the effects of oestrogen replacement therapy (ERT) on lipid and coagulation factors fail to fully explain the reduction in cardiovascular risk in postmenopausal women, extrahepatic actions of female sex steroids have become a focus of interest. It has become apparent that oestrogens exert significant effects on blood vessels, both structural and functional. These may represent other important ways of cardioprotection in postmenopausal women using ERT.
Introduction
As the effects of oestrogen replacement therapy (ERT) on lipid and coagulation factors fail to fully explain the reduction in cardiovascular risk in postmenopausal women, extrahepatic actions of female sex steroids have become a focus of interest. It has become apparent that oestrogens exert significant effects on blood vessels, both structural and functional. These may represent other important ways of cardioprotection in postmenopausal women using ERT.
Myoproliferative disorders of the vasculature, such as intimal hyperplasia, are a recognized secondary response to mechanical challenges to blood vessels such as shear stress, and surgical interventions such as endarterectomy, balloon angioplasty and arterialization of veins in grafts. However, primary intimal hyperplasia in coronary arteries is not unknown, and population of the coronary intima by vascular smooth muscle cells has been described in humans as young as several months (Sims et al., 1993) . Intimal hyperplasia has been described as a primary occurrence in stenotic human coronary arteries. In a histological study of directional atherectomy specimens from individuals with primary coronary occlusion, intimal hyperplasia was identified in 44% of cases, predominantly in younger people (Miller et al., 1993) .
In-vivo intimal hyperplasia occurs in both arteries and veins. Although it is widely known as a pathological process, it may have physiological, adaptive function to stress. A certain degree of intimal thickening is present in most veins, where it is related to factors such as age, venous pressure, local haemodynamic effects, and perhaps hypoxia. It is particularly prominent in dependent, unsupported veins, possibly attributable to the higher intraluminal pressures at these sites (Charles and Gresham, 1993) .
Histologically, intimal hyperplasia can be difficult to distinguish from atherosclerosis, and indeed it has been known under the name 'graft arteriosclerosis'. Following endothelial injury, a response is initiated which involves activation of vascular smooth muscle cells in the tunica muscularis media. These cells can migrate from the media to the intimal layer, proliferate, change their phenotype from contractile to synthetic, and commence the production of extracellular matrix and collagen, which is then accumulated in the subendothelial space, thus leading to intimal thickening. Intimal infiltration by inflammatory cells can also be seen. Processes such as lipid deposition and intraplaque haemorrhage are usually only seen in atheromata and do not occur in intimal hyperplasia.
There may be an effect of gender on the development of intimal hyperplasia in animals, although it remains controversial whether this is due to a greater resistance of female tissues to the development of an intimal reaction or to a direct or indirect effect of female sex steroids (Foegh et al., 1995) . However, in a recent study on intimal injury in rat carotid arteries it has been demonstrated that the sex difference in myointimal proliferation after vascular damage is oestrogen dependent (Chen et al., 1996) . This is not surprising, as oestrogen has been shown to inhibit one of the key events in intimal hyperplasia, smooth muscle cell proliferation, in several animal models (Cheng et al., 1991; Vargas et al., 1993) Oestradiol treatment in rabbits with aortic transplants has been shown to preserve the ultrastructure of endothelial cells and to inhibit macrophage infiltration of the intima (Cheng et al., 1991) , possibly by direct action, as both smooth muscle cells and macrophages possess oestrogen receptors (Gulshan et al., 1990) . Further, oestrogen may reduce connective tissue accumulation in the vascular wall, with changes to the collagen: elastin ratio, thus making blood vessels more distensible (Fisher, 1977) .
However, it remains difficult to extrapolate evidence obtained from animal research to events occurring in humans. To date we lack conclusive data relating to the in-vivo or invitro response of human female blood vessels to events leading to intimal hyperplasia, and to the effect of 17β-oestradiol on this process.
The objective of this study was to develop an in-vitro vascular model that would facilitate the study of the effect of sex steroids on blood vessels under controlled conditions, using all human material. In the following a new model is introduced for induction of intimal hyperplasia in human ovarian veins cultured in human postmenopausal serum, and its potential modulation by sex steroid exposure.
Materials and methods
An 80 ml sample of blood was collected from each of 25 healthy, postmenopausal women who had given verbal consent. All had at least 6 months amenorrhoea. Menopausal status was confirmed biochemically, with a serum follicle stimulating hormone (FSH) concentration of Ͼ30 IU and serum oestradiol of Ͻ70 pmol/l. The blood samples were centrifuged at 2000 g for 30 min. The serum was then filtered through a 0.2 µm bacterial filter and incubated for 30 min at 56°C in a water-bath. Following heat-inactivation the sera were pooled, aliquoted, and stored at -20°C until required.
Fifteen salpingo-oophorectomy specimens were obtained from a routine gynaecological theatre list. All operations were performed for benign conditions, mainly menstrual disorders. Ovaries with the attached segment of infundibulo-pelvic ligament were immersed in sterile normal saline solution and transported to the laboratory at ambient temperature. All specimens were processed within 4 h of surgery. The infundibulo-pelvic ligaments were dissected using fine ophthalmic forceps and scissors under sterile conditions, and the ovarian vein plexus were identified. Vein segments of~0.5 cm length were excised with a scalpel blade. The adventitia was cleaned from excess fatty tissue, the vein segments were opened longitudinally and pinned into culture dishes containing Sylgard resin (BDH, Lutterworth, UK) with the endothelium uppermost.
One segment from each vein (n ϭ 15) was fixed in 10% formalin uncultured to serve as a paired control. Adjacent segments (n ϭ 15) were cultured as described below. Additionally, 10 paired vein segments were cultured in with added 17β-oestradiol in pharmacological concentration (10 -6 M), and with the addition of the biologically inert 17α-oestradiol (10 -6 M) to serve as controls.
A further five vein segments each were cultured in a dose response experiment with 17β-oestradiol in pharmacological through to physiological concentrations (10 -6 to 10 -9 M).
The vein segments were immersed into culture medium, containing phenol-free Roswell Park Memorial Institute medium, N-glutamine, 50 µg/ml penicillin and 50 µg/ml streptomycin (all from Sigma, Dorset, UK). Instead of using fetal calf serum as described in the literature, the media were supplemented with 20% heat-inactivated pooled postmenopausal serum. The culture medium was changed every 48 h. The vein segments were cultured for 14 days in total in a humidified chamber at 37°C. On day 15 the culture medium was discarded and the tissue was covered with 10% formalin and fixed for 48 h. The vein segments were then paraffin-embedded. Sections of 5 µm thickness were cut using the Leica RM2035 microtome and mounted on silane-coated glass slides.
To confirm the presence of intact endothelium on every vein segment, the sections were stained with mouse monoclonal CD31 endothelial antibody following a standard immunocytochemistry protocol. To demonstrate vascular wall structure, the sections were stained with anti-α-smooth muscle actin, again following a standard immunocytochemistry protocol, using mouse monoclonal anti-α-smooth muscle actin antibody (Dako, Cambridge, UK) at a concentration of 1:500; subsequently they were counterstained in Miller's elastin stain (Raymond Lamb, London, UK).
To allow the assessment of cellularity, the nuclei were marked by staining with Mayer's haematoxylin. For this purpose the sections were dewaxed and taken to water, then stained by immersion in Mayers' haematoxylin solution for 10 min, washed and mounted.
Intimal thickness was measured using light microscopy and image analysis. The equipment used included an Axioplan light microscope (Carl Zeiss, Herefordshire, UK), a colour video camera (Sony DXC-151P) with a camera adapter (Sony CMA-151P), a RasterOps 24STV graphics display board and an Apple Macintosh computer (Centris 650), with an image analysis system for Macintosh (Image 1.52), at 20ϫ10 magnification. Intima-media thickness was measured four times in five high-power fields per slide (20 measurements per blood vessel) by two observers blinded to the culture conditions. The measurement was performed from the luminal endothelial margin to the circular layer of medial muscle (see below).
Nuclei were counted using light microscopy as above. The image of the intimal layer at a magnification of 100ϫ10 was captured and visualized on the monitor. The number of positive nuclei per high power field was counted on 15 high power fields per slide. The nuclei were counted in the intimal layer, excluding the loose neointimal layer, as this was not present in all specimens.
The reproducibility and inter-observer variability of the intimal thickness measurement was assessed on 15 sections. The vein segment was centralized in the visual field of the microscope at a magnification of 20ϫ10. Each observer captured the image on the image analysis program after focusing, and measured the distance from the endothelial margin to the intima-circular medial muscle layer interface 10 times. A Bland-Altman plot (Bland and Altman, 1986) for the inter-observer error was generated (Figure 1 ). The inter-observer variability was 8 % [95% confidence interval (CI) 3.5, 12.5].
Intimal thickness of each blood vessel was obtained from the mean of both observers. Differences in mean intimal thickness between uncultured and cultured vein segments with and without added sex steroids were analysed for statistical significance using Student's t- test for paired variables. The relationship between the baseline intimal thickness in uncultured vessels and the thickness of the neointima following culture was examined using simple regression analysis.
Results
All fresh and cultured specimens had largely intact endothelial coverage as demonstrable with CD31 staining (Figure 2 ). Any endothelial coverage defects occurred near the cut edges of the vein segments and did not extend beyond~25% of the endothelial surface in any of the specimens.
The vascular wall in fresh ovarian vein specimens consists of four distinct layers. On the luminal side of the vessel there is a layer of endothelial cells, followed by three muscular layers. The first muscle layer consists of loosely scattered, longitudinally orientated cells, embedded in variable amounts of extracellular matrix. Ovarian veins do not possess a lamina elastica interna, therefore this layer is in a continuum with the subendothelial extracellular matter. The next layer consists of more densely packed, circular muscle, followed by a further coat of longitudinal muscle (Figure 3) . In a proportion of veins, a degree of pre-existent intimal thickening was observed. Both focal and generalized thickening was observed. This was most prominent in veins from specimens where large uterine fibroids had been present.
Intimal hyperplasia, consisting of thickening of the intimamedia layer, accumulation of actin positive cells and extracellular matrix, was induced to a varying degree in all cultured blood vessels. A layer of loosely stratified cells was observed overlying the endothelial margin of the blood vessel in eight of the 15 cultured blood vessels (Figure 4) . This layer will be referred to as the 'proliferative layer'. The proliferative cell layer was negative for CD31. Some cells within this layer were weakly positive for α-smooth muscle actin. Where a proliferative layer has formed, it extended over the cut edges of the vein section, and in some instances included the adventitial side.
The mean intimal thickness increased from 8.25 µm (95% CI 6.3, 10.2) in fresh veins to 15.7 µm (95% CI 13.6, 17.8) in cultured specimens ( Figure 5 ). This difference was statistically significant (P ϭ 0.0001). There was no significant correlation between the baseline intimal thickness of the fresh vein and the degree of subsequent neointimal development in culture (R ϭ 0.21, P ϭ 0.45) (Figure 6 ).
The addition of 17β-oestradiol in a pharmacological concentration (10 -6 M) reduced intimal thickness from 15.1 µm (95% CI 11.9, 18.3) in the 10 paired veins cultured in postmenopausal serum without sex steroid addition, to 8.85 µm (95% CI 6.9, 10.8) (Figure 7) . This difference was statistically significant (P ϭ 0.008). Although the overall thickness of the intima was reduced, the addition of oestrogen did not seem to affect the development of a proliferative layer, as again it was present in more than half of the blood vessels. There was no statistical difference in the intimal thickness between the various doses of oestradiol (Table I) , but only the pharmacological dose produced a significantly thinner intima when compared to veins cultured without sex steroid addition.
In veins cultured with the addition of the inert 17α-oestradiol mean intimal thickness was 14.3 µm (95% CI 11.4, 17.2). This was not significantly different from veins cultured without the addition of sex steroids (P ϭ 0.23) (Figure 7) .
The mean number of nuclei per high power field in the 1452 intimal layer of uncultured veins was 10.9 (95% CI 9.5, 12.5). This rose to an average of 14.05 (95% CI 12.5, 15.6) nuclei per high power field in cultured veins. This increase was statistically significant (P ϭ 0.001). In the intima of vein segments cultured with the addition of 17β-oestradiol in pharmacological concentration (10 -6 M) the nuclear count per high power field was significantly lower than that of veins cultured without the addition of sex steroids (11.6 nuclei per high power field; 95% CI 9.94, 13.26). The addition of 17α-oestradiol did not lead to a significant change in intimal nuclear count, when compared to veins cultured without steroid addition. The mean number of nuclei per high power field in these control segments was 12.85 (95% CI 11.83, 13.86).
Discussion
The development of intimal hyperplasia in humans is difficult to study, as early changes are asymptomatic, and at that stage usually clinically not detectable. Apart from necropsy material, we hence have to rely on in-vitro work in the understanding of myointimal disease. Intimal thickening in arteries may occur at a very young age, and with considerable regional variations. In a histopathological study comparing internal thoracic arteries and anterior descending coronary arteries in 293 necropsies, Sims et al. (1993) described intimal hyperplasia in coronary arteries at birth, with progressive increase with years. These changes were absent in the internal thoracic artery. In this particular study, the authors found that the presence of a thickened intima corresponded with a deficient lamina elastica interna. Coronary arteries have a relatively weak lamina elastica interna compared to other arteries, which may particularly predispose them to myointimal hyperplasia, as it facilitates the migration of smooth muscle cells from the media to the intima. This model would also explain the frequency of intimal thickening in veins, as in most veins the lamina elastica interna is deficient or even absent. Although several animal models have used arteries for culture, and a model using human mammary artery has also been described (Holt et al., 1992) , this particular characteristic makes veins particularly suitable for use in models of induction of intimal hyperplasia, and therefore in our model for study of intimal hyperplasia ovarian veins were used. The vascular culture model described above has proved successful, as it was possible to maintain, over a 14 day period, viability in human ovarian veins in culture. Further, it was possible to induce a significant degree of intimal hyperplasia, using culture media supplemented with 20% human serum. Although it will remain difficult to infer invivo mechanisms from in-vitro experiments, using all human materials in vascular culture work eliminates the necessity to extrapolate data across species.
The absence of the lamina elastica interna in human ovarian veins represents both the main advantage and difficulty of this model. Although on one hand this characteristic facilitates the induction of intimal hyperplasia, it makes a clear, functional as well as histological definition of an intima problematic, as the lack of microanatomical separation between intima and media results in the confluence of the subendothelial ground substance with the extracellular matrix, in which the first loose muscular layer is embedded. In a study looking at the fine structure of the human ovarian vein, Stones et al. (1994) described this first muscle layer as part of the media. However, as the amount of both extracellular matrix and muscle in this layer was variable, and as it was impossible to determine the exact transition of intima into media on light microscopy, the intimal thickness measurements were taken to include this layer. The subsequent, circular muscle layer was consistent and clearly demarcated, allowing accurate measurement as reflected by a low inter-observer variability. Functionally, it makes sense to consider both confluent layers as the 'intima', as they are likely to be affected to the same degree by environmental changes. Any increase in extracellular matrix production by vascular smooth muscle cells can be expected to appear as a thickening of the already present ground substance within this layer. Further, as it is not the absolute thickness of this layer, but changes in intimal thickness of paired specimens, measurements taken as described above would not lack validity.
A pre-existing degree of focal or diffuse intimal thickening was observed in several ovarian veins. This is in keeping with the observation of Charles and Gresham (1993) , who examined human veins from different sites of the body, and found focal intimal thickening in native veins, possibly related to venous pressure and local haemodynamic effects. In the case of human ovarian veins we have to take into account the increased circulatory demands of female reproductive life, with increase in venous pressure in pregnancy and in association with large uterine fibroids. The extent of increased haemodynamic load and its duration necessary to induce intimal changes remains uncertain, but the prominent musculature of the ovarian vein is a clear reflection of the degree of stress it is designed to cope with.
The results of the above study also demonstrate that oestrogen in pharmacological doses may reduce the extent of intimal thickening in cultured human ovarian veins. Although a similar effect of physiological doses of oestrogen could not be demonstrated, the number of specimens examined in the dose-response experiment was small and may not have been sufficient to detect a significant change.
The mechanism of this effect of oestrogen on the ovarian vein intima is not readily apparent. Although both intimal thickness and cellularity of the intima, as reflected in the mean number of nuclei present, were clearly decreased in oestrogentreated veins, the addition of 17β-oestradiol did not affect the development of a superimposed proliferative layer. As this is the first experimental study looking at intimal hyperplasia in human ovarian veins, it is not possible to compare our results those of with other authors. However, several authors have described an inhibitory effect of oestrogen on myointimal proliferation in animal experiments both in vivo and in vitro. Oestrogen has been shown to suppress proliferation in vascular smooth muscle cells, but migration of the vascular smooth muscle cells from the media to the intima may occur as an independent event (Cheng et al., 1991) . In a study on inhibition of myointimal hyperplasia in rabbit aorta allografts, the presence of vascular smooth muscle cells in the intima of grafts harvested from oestrogen-treated animals has been described (Vargas et al., 1993) . The smooth muscle cells were morphologically different from those seen in untreated animals, demonstrating little or no vacuolization. This may suggest that, although migration still occurred, the vascular smooth muscle cells did not undergo the transformation from contractile to synthetic phenotype, which seems to be associated with the increased matrix elaboration seen in myointimal disorders.
A recent study demonstrated a reduction in the crosssectional area of the intima in aortae of pregnant guineapigs compared to non-pregnant animals (Jovanovic, 1997) . However, changes to the medial layer were not observed, and the authors concluded that the intimal changes were secondary to a selective hypotrophy of endothelial cells. In our study, the observed changes involved the whole intima-media layer, as evident by the reduction in cell counts in the subendothelial layer following oestrogen treatment. Further, a selective reduction in endothelial cell size would not have led to demonstrable decrease in intima-media thickness, as the contribution of the endothelial cell dimensions to the overall intima-media thickness is too small.
The 'proliferative' layer, the layering of loose cells over the endothelium, may originate from these migrating smooth muscle cells. Particularly in ovarian veins, where the lamina elastica interna is grossly deficient or absent, migration of smooth muscle cells is a likely mechanism. In this study, the new layers of cells lining the luminal surface were not recognized by the endothelial cell marker anti-CD31, which would make it appear unlikely that these cells originate from the endothelium. Further, they were not only seen along the endothelial surface, but also along the cut edges and the adventitial side. In a culture of human saphenous veins Slomp et al. (1996) also described this phenomenon. They observed that the cellular overgrowth in fact started over the cut edges of the specimens, and then advanced over the endothelial surface. It formed in vein segments that had not been properly pinned down into the resin, as well as in those left tubular rather than opened. The proliferative layer in their work was also not recognized by endothelial markers; however, some cells within this layer stained positive for a fibroblast marker, the 5B5 antibody. Interestingly, no cells in the vascular wall had stained positive for the fibroblast marker prior to culture.
If, as deduced by Slomp et al. these cells originated over the cut edges, i.e. in the medial/adventitial layer, it would appear that the proliferative layer, as defined in this study, would develop independently from bona fide intimal hyperplasia. This would also explain the observed discordance between the effect of oestrogen on the intima and its cellularity on one hand, and its effect-or rather the lack of it-on the formation of this proliferative, loose proliferative covering on the other.
In conclusion, organ culture of human ovarian veins in postmenopausal serum-supplemented media is a suitable model for the study of vascular changes, such as induction of intimal hyperplasia. Oestrogen in pharmacological doses reduces the degree of intimal hyperplasia observed in cultured human ovarian veins in vitro, the mechanisms of which require further investigation.
